Currently out of the existing stock ratings of Luca Issi, 90 are a HOLD (38.96%), 140 are a BUY (60.61%), 1 are a SELL (0.43%).

Luca Issi

Work Performance Price Targets & Ratings Chart

Analyst Luca Issi, currently employed at RBC, carries an average stock price target met ratio of 39.83% that have a potential upside of 33.84% achieved within 122 days.

Luca Issi’s has documented 450 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 19-Sep-2025.

Wall Street Analyst Luca Issi

Analyst best performing recommendations are on FDMT (4D MOLECULAR THERAPEUTICS ).
The best stock recommendation documented was for FDMT (4D MOLECULAR THERAPEUTICS ) at 1/29/2024. The price target of $25 was fulfilled within 7 days with a profit of $6.98 (38.73%) receiving and performance score of 55.34.

Average potential price target upside

of $53.79 (27.37%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $42.4 (25.84%) on ASND (ASCENDIS PHARMA AS).
of $26.77 (70.82%) on IONS (IONIS PHARMACEUTICALS).

ALLO Allogene Therapeutics ALNY Alnylam Pharmaceuticals ARWR Arrowhead Pharmaceuticals BLUE Bluebird bio CRSP Crispr Therapeutics AG DRNA Dicerna Pharmaceuticals IONS Ionis Pharmaceuticals RGNX Regenxbio WVE Wave Life Sciences Ltd SGMO Sangamo Therapeutics ADVM Adverum Biotechnologies CRBU Caribou Biosciences EDIT Editas Medicine FIXX Homology Medicines NTLA Intellia Therapeutics GRPH Graphite Bio VERV Verve Therapeutics MRNA Moderna MGTX MeiraGTx Holdings PLC BEAM Beam Therapeutics BMRN Biomarin Pharmaceutical QURE Uniqure NV FDMT 4D Molecular Therapeutics APLS Apellis Pharmaceuticals DYN Dyne Therapeutics RARE Ultragenyx RNA Avidity Biosciences KRRO Frequency Therapeutics LXEO Lexeo Therapeutics, Common Stock ASND Ascendis Pharma AS

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Brian Cheng (JPMORGAN)